Prognosis Risk of Urosepsis in Critical Care Medicine: A Prospective Observational Study

Table 1

Demographic data and clinical features of the urosepsis and the control groups.

	Urosepsis; ()	Control; ()		value
Age (years)	43.6 ± 12.5	57.3 ± 19.3	−3.886	<0.001
Gender (male/female, %)	17/19 (47%/53%)	45/31 (59%/41%)	1.421	0.233
APACHE II score	20.3 ± 5.6	21.8 ± 6.1	−1.247	0.215
SOFA score	5.8 ± 1.9	5.1 ± 2.2	1.640	0.104
HLA-DR (%)	56.47 ± 21.63	49.85 ± 24.47	1.386	0.168
Combination diseases	1.02 ± 0.84	2.36 ± 1.44	−5.174	<0.001
Time before being sent to ICU (hours)	9.2 ± 6.6	7.2 ± 4.9	1.798	0.075
Organ dysfunction time (hours)	4.7 ± 2.4	7.2 ± 4.5	−3.124	0.002
WBC count (×10^9/L)	6.3 ± 5.5	14.7 ± 4.8	−8.249	<0.001
PLT count (×10^9/L)	83.2 ± 34.6	138.9 ± 45.1	−6.548	<0.001
Serum creatinine (μmol/L)	125.9 ± 49.8	121.2 ± 56.4	0.427	0.670
Bilirubin (μmol/L)	15.9 ± 3.8	16.4 ± 3.2	−0.726	0.469
Mean arterial pressure (mmHg)	92.8 ± 19.2	99.3 ± 17.7	−2.038	0.053
Oxygenation index	214.1 ± 45.3	208.3 ± 56.5	0.539	0.591
PCT (ng/mL)	129.3 ± 40.8	41.2 ± 38.4	11.114	<0.001
ICU stay (days)	11.6 ± 5.5	14.8 ± 7.1	−2.384	0.019
Total hospitalization (days)	16.2 ± 6.9	18.1 ± 9.2	−1.100	0.274
Mechanical ventilation	20 (56%)	53 (70%)	2.165	0.141
Vasoactive drugs use	17 (47%)	29 (38%)	0.829	0.362
CRRT	10 (28%)	21 (28%)	0.000	0.987
Extracorporeal liver assist device (artificial liver)	2 (6%)	5 (7%)	0.044	0.834
Positive blood cultures	27 (75%)	23 (30%)	19.783	<0.001
28-day mortality	2 (6%)	28 (37%)	12.193	<0.001
90-day mortality	2 (6%)	32 (42%)	15.436	<0.001

APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment; ICU, intensive care unit; WBC, white blood cell; PLT, platelet; PCT, procalcitonin; CRRT, continuous renal replacement therapy.